Advance Search
ZOU Jinchan, LIU Xiaomin. Research progress on the protective effect of sodium-glucose cotransporter 2 inhibitor on kidney in patients with type 2 diabetes mellitus[J]. Journal of Clinical Medicine in Practice, 2021, 25(23): 129-132. DOI: 10.7619/jcmp.20212879
Citation: ZOU Jinchan, LIU Xiaomin. Research progress on the protective effect of sodium-glucose cotransporter 2 inhibitor on kidney in patients with type 2 diabetes mellitus[J]. Journal of Clinical Medicine in Practice, 2021, 25(23): 129-132. DOI: 10.7619/jcmp.20212879
shu

Research progress on the protective effect of sodium-glucose cotransporter 2 inhibitor on kidney in patients with type 2 diabetes mellitus

  • Department of Endocrinology,the First Affiliated Hospital of Harbin Medical University,Harbin,Heilongjiang,150001

More Information
  • Received Date: July 17, 2021
  • Available Online: December 20, 2021
    Graphical Abstract
    • Abstract

  • Sodium-glucose cotransporter 2 inhibitor is a new type of non-insulin-dependent oral hypoglycemic drug,which can reduce the reabsorption of glucose in the original urine,increase the excretion of urinary glucose and reduce blood sugar by inhibiting the activity of sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubule.SGLT2i can also reduce blood pressure,arterial stiffness and blood uric acid,regulate renal hemodynamics,inhibit renin-angiotensin system (RAS) and sympathetic nervous system (SNS),reduce inflammation as well as oxidative stress and improve kidney hypoxia,thereby playing the role of kidney protection.In this review,the role of SGLT2 in the regulation of renal glucose metabolism and the research progress and corresponding mechanism of SGLT2i on renal protection were reviewed.

    • FullText(HTML)
    • References (28)
  • [1]
    CHERNEY D Z,ODUTAYO A,ARONSON R, et al.Sodium glucose cotransporter-2 inhibition and cardiorenal protection: JACC review topic of the week[J].J Am Coll Cardiol,2019,74(20): 2511-2524. doi: 10.1016/j.jacc.2019.09.022
    [2]
    FUJITA Y,INAGAKI N.Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of action[J].J Diabetes Investig,2014,5(3): 265-275. doi: 10.1111/jdi.12214
    [3]
    WILDING J P.The role of the kidneys in glucose homeostasis in type 2 diabetes: clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors[J].Metabolism,2014,63(10): 1228-1237. doi: 10.1016/j.metabol.2014.06.018
    [4]
    李航.肾脏在血糖调节中的作用[J].中国糖尿病杂志,2016,24(2): 184-186. doi: 10.3969/j.issn.1006-6187.2016.02.024
    [5]
    NI L,YUAN C,CHEN G, et al.SGLT2i: beyond the glucose-lowering effect[J].Cardiovasc Diabetol,2020,19(1): 98. doi: 10.1186/s12933-020-01071-y
    [6]
    李克柔,安赤颖,刘晓民.钠-葡萄糖共转运蛋白2抑制剂与酮症酸中毒: 关注降糖药的利与弊[J].中华糖尿病杂志,2019,11(4): 230-233. doi: 10.3760/cma.j.issn.1674-5809.2019.04.002
    [7]
    CASTAÑEDA A M,DUTRA-RUFATO A,JUAREZ M J, et al.Sodium-glucose cotransporter 2 inhibitors (SGLT2i): renal implications[J].Int Urol Nephrol,2021,53(2): 291-299. doi: 10.1007/s11255-020-02585-w
    [8]
    SALEEM F.Dapagliflozin: cardiovascular safety and benefits in type 2 diabetes mellitus[J].Cureus,2017,9(10): e1751.
    [9]
    HEERSPINK H J L,STEFÁNSSON B V,CORREA-ROTTER R, et al.Dapagliflozin in patients with chronic kidney disease[J].N Engl J Med,2020,383(15): 1436-1446. doi: 10.1056/NEJMoa2024816
    [10]
    PERKOVIC V,JARDINE M J,NEAL B, et al.Canagliflozin and renal outcomes in type 2 diabetes and nephropathy[J].N Engl J Med,2019,380(24): 2295-2306. doi: 10.1056/NEJMoa1811744
    [11]
    WILLIAMS D M,NAWAZ A,EVANS M.Renal outcomes in type 2 diabetes: a review of cardiovascular and renal outcome trials[J].Diabetes Ther,2020,11(2): 369-386. doi: 10.1007/s13300-019-00747-3
    [12]
    中华医学会肾脏病学分会专家组.糖尿病肾脏疾病临床诊疗中国指南[J].中华肾脏病杂志,2021,37(3): 255-304. doi: 10.3760/cma.j.cn441217-20201125-00041
    [13]
    中华医学会糖尿病学分会.中国2型糖尿病防治指南(2020年版)[J].国际内分泌代谢杂志,2021,41(5): 482-548. doi: 10.3760/cma.j.cn121383-20210825-08063
    [14]
    SANIDAS E A,PAPADOPOULOS D P,HATZIAGELAKI E, et al.Sodium glucose cotransporter 2 (SGLT2) inhibitors across the spectrum of hypertension[J].Am J Hypertens,2020,33(3): 207-213.
    [15]
    SCHEEN A J.Effect of SGLT2 inhibitors on the sympathetic nervous system and blood pressure[J].Curr Cardiol Rep,2019,21(8): 70. doi: 10.1007/s11886-019-1165-1
    [16]
    BAILEY C J.Uric acid and the cardio-renal effects of SGLT2 inhibitors[J].Diabetes Obes Metab,2019,21(6): 1291-1298. doi: 10.1111/dom.13670
    [17]
    SCHEEN A J.Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus[J].Nat Rev Endocrinol,2020,16(10): 556-577. doi: 10.1038/s41574-020-0392-2
    [18]
    TONNEIJCK L,MUSKIET M H,SMITS M M, et al.Glomerular hyperfiltration in diabetes: mechanisms,clinical significance,and treatment[J].J Am Soc Nephrol,2017,28(4): 1023-1039. doi: 10.1681/ASN.2016060666
    [19]
    BARUTTA F,BERNARDI S,GARGIULO G, et al.SGLT2 inhibition to address the unmet needs in diabetic nephropathy[J].Diabetes Metab Res Rev,2019,35(7): e3171. http://www.onacademic.com/detail/journal_1000042268662699_ddeb.html
    [20]
    THOMAS M C,CHERNEY D Z I.The actions of SGLT2 inhibitors on metabolism,renal function and blood pressure[J].Diabetologia,2018,61(10): 2098-2107. doi: 10.1007/s00125-018-4669-0
    [21]
    HERAT L Y,MAGNO A L,RUDNICKA C, et al.SGLT2 inhibitor-induced sympathoinhibition: a novel mechanism for cardiorenal protection[J].JACC Basic Transl Sci,2020,5(2): 169-179. doi: 10.1016/j.jacbts.2019.11.007
    [22]
    KLUGER A Y,TECSON K M,LEE A Y, et al.Class effects of SGLT2 inhibitors on cardiorenal outcomes[J].Cardiovasc Diabetol,2019,18(1): 99. doi: 10.1186/s12933-019-0903-4
    [23]
    HEERSPINK H J L,PERCO P,MULDER S, et al.Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease[J].Diabetologia,2019,62(7): 1154-1166. doi: 10.1007/s00125-019-4859-4
    [24]
    TSAI S F,TARNG D C.Anemia in patients of diabetic kidney disease[J].J Chin Med Assoc,2019,82(10): 752-755. doi: 10.1097/JCMA.0000000000000175
    [25]
    HEERSPINK H J L,PERKINS B A,FITCHETT D H, et al.Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects,potential mechanisms,and clinical applications[J].Circulation,2016,134(10): 752-772. doi: 10.1161/CIRCULATIONAHA.116.021887
    [26]
    TENTOLOURIS A,VLACHAKIS P,TZERAVINI E, et al.SGLT2 inhibitors: a review of their antidiabetic and cardioprotective effects[J].Int J Environ Res Public Heal,2019,16(16): 2965. doi: 10.3390/ijerph16162965
    [27]
    PACKER M.Mechanisms leading to differential hypoxia-inducible factor signaling in the diabetic kidney: modulation by SGLT2 inhibitors and hypoxia mimetics[J].Am J Kidney Dis,2021,77(2): 280-286. doi: 10.1053/j.ajkd.2020.04.016
    [28]
    BESSHO R,TAKIYAMA Y,TAKIYAMA T, et al.Hypoxia-inducible factor-1α is the therapeutic target of the SGLT2 inhibitor for diabetic nephropathy[J].Sci Rep,2019,9(1): 1-12.
    • Related Articles

  • Related Articles

    [1]ZHU Mingming, LI Zonghu, ZHENG Xianling, WANG Yingxia, ZHANG Shujie. Relationships of blood glucose fluctuation with serum Omentin-1 and oxidative stress factors in patients with type 2 diabetes mellitus[J]. Journal of Clinical Medicine in Practice, 2023, 27(20): 113-117. DOI: 10.7619/jcmp.20231747
    [2]JIANG Liyan, PAN Hongbo, CHEN Kun, XIA Li, MU Yujing. The serum levels of serum ferritin and vitamin D in diabetic peripheral neuropathy and their relationships with oxidative stress[J]. Journal of Clinical Medicine in Practice, 2023, 27(5): 110-113, 118. DOI: 10.7619/jcmp.20222301
    [3]LIU Huan, LIU Yongxia, LIU Yan, ZHAO Ni. Changes of physiological indexes and oxidative stress indexes in elderly patients with essential hypertension and their significance[J]. Journal of Clinical Medicine in Practice, 2020, 24(23): 88-91. DOI: 10.7619/jcmp.202023027
    [4]WANG Fang. Correlation between serum vitamin level, oxidative stress injury and preeclampsia in pregnant women[J]. Journal of Clinical Medicine in Practice, 2020, 24(15): 87-89. DOI: 10.7619/jcmp.202015024
    [5]ZHU Ting, DONG Lin, DENG Yuezhen. Effects of liraglutide on oxidative stress status in newly-diagnosed type 2 diabetes mellitus patients with obesity[J]. Journal of Clinical Medicine in Practice, 2018, (5): 29-31. DOI: 10.7619/jcmp.201805009
    [6]ZHANG Li, ZHANG Hengdong. Effects of calcium disodium and water-soluble vitamins on serum T lymphocytes and oxidative stress in patients with occupational lead poisoning[J]. Journal of Clinical Medicine in Practice, 2017, (15): 34-36,40. DOI: 10.7619/jcmp.201715009
    [7]LIU Anning, ZHANG Gaosheng, WANG Liang, HUANG Jing. Influence of lipoic acid injection on the oxidative stress state and local microcirculation of patients with diabetic foot[J]. Journal of Clinical Medicine in Practice, 2017, (1): 56-58. DOI: 10.7619/jcmp.201701016
    [8]GU Zhihong. Effect of intravenous immunoglobulin on inflammatory reaction and oxidative stress reaction of children with Kawasaki disease[J]. Journal of Clinical Medicine in Practice, 2016, (5): 103-106. DOI: 10.7619/jcmp.201605031
    [9]FENG Yamin, XU Jiarong, YOU Na, ZHENG Haining, ZHU Qun. Influence Of thioctic acid on oxidative stress and microalbuminuria in patients with early diabetic nephropathy[J]. Journal of Clinical Medicine in Practice, 2014, (3): 95-97. DOI: 10.7619/jcmp.201403032
    [10]CHENG Xinqin, XIANG Min. Relationship between oxidative stress and cellular adhesion molecule changes in diabetic patients with hyperglycemia crisis[J]. Journal of Clinical Medicine in Practice, 2014, (3): 23-25. DOI: 10.7619/jcmp.201403007

  • Cited by

    Periodical cited type(7)

    1. 高宇，沈聪. 中药面膜联合5-氨基酮戊酸光动力疗法及异维A酸治疗中重度痤疮. 中国美容医学. 2025(01): 87-91 .
    2. 袁秀丽，杨晓萌，田雅娟. 超分子水杨酸联合强脉冲光对中重度痤疮病人皮肤屏障功能及痤疮评分系统的影响. 安徽医药. 2025(04): 721-724 .
    3. 陈培元，李正，欧阳玲，林双娇，陈燕婷，宋维芳. ALA-PDT联合他克莫司软膏对玫瑰痤疮患者症状缓解时间及生活质量的影响. 中国医学创新. 2024(29): 101-104 .
    4. 王恩波，张庆瑞，胡玮. 5-氨基酮戊酸光动力疗法联合过氧化苯甲酰凝胶治疗面部中重度痤疮疗效观察. 中国美容医学. 2024(11): 48-51 .
    5. 刘华，韩婷梅，肖飞. 不同浓度5-氨基酮戊酸光动力疗法辅助治疗面部顽固性扁平疣的效果对比. 中国药物滥用防治杂志. 2024(11): 2074-2076 .
    6. 唐清宁. 光动力治疗非肿瘤性皮肤病的研究进展. 中国冶金工业医学杂志. 2023(05): 513-515 .
    7. 李昕. 光动力与红蓝光分别联合异维A酸治疗中重度痤疮的临床观察. 现代诊断与治疗. 2021(20): 3261-3263 .

    Other cited types(2)

Catalog

    Get Citation
    PDF
    XML
    Article views (315) PDF downloads (20) Cited by(9)
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    © 2020 《实用临床医药杂志》编辑部

    Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807

    苏公网安备 32100302010246号

    Supported by: Beijing Renhe Information Technology Co., Ltd.   Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return